Last update Oct. 5, 2023
Incompatible
We do not have alternatives for Διυδροεργοτοξίνη μεθανοσουλφονική; Συν-δεργοκρίνη μεθανοσουλφονική.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Διυδροεργοτοξίνη μεθανοσουλφονική; Συν-δεργοκρίνη μεθανοσουλφονική is Co-dergocrine Mesilate, codergocrine in Greek.
Is written in other languages:Διυδροεργοτοξίνη μεθανοσουλφονική; Συν-δεργοκρίνη μεθανοσουλφονική is also known as
Διυδροεργοτοξίνη μεθανοσουλφονική; Συν-δεργοκρίνη μεθανοσουλφονική belongs to this group or family:
Main tradenames from several countries containing Διυδροεργοτοξίνη μεθανοσουλφονική; Συν-δεργοκρίνη μεθανοσουλφονική in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 2.25 ± 0.65 | % |
Molecular weight | 660 | daltons |
Protein Binding | 81 | % |
VD | 2 | l/Kg |
Tmax | 1 | hours |
T½ | 7.5 ± 1.2 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a mixture of hydrogenated ergot alkaloids used as an adjunct in the symptomatic treatment of mild to moderate dementia in the elderly. It is also used in the treatment of hypertension, migraine and peripheral vascular disease. Oral administration in three daily doses. Also sublingually, intramuscularly, subcutaneously or by intravenous infusion.
At the date of the last update we did not find published data on its excretion in breast milk.
Its pharmacokinetic data (very large volume of distribution and moderately high molecular weight) make it unlikely to pass into breast milk in clinically significant quantities.
Like all ergot derivatives, it is a dopaminergic agonist and therefore reduces prolactin secretion (Dominiak 1988) and may suppress lactation.
See below the information of this related product: